These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 27638639)

  • 1. Assessment of non-linear combination effect terms for drug-drug interactions.
    Koch G; Schropp J; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2016 Oct; 43(5):461-79. PubMed ID: 27638639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions between drugs and occupied receptors.
    Tallarida RJ
    Pharmacol Ther; 2007 Jan; 113(1):197-209. PubMed ID: 17079019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parallel dose-response curves in combination experiments.
    Sühnel J
    Bull Math Biol; 1998 Mar; 60(2):197-213. PubMed ID: 9559575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target mediated drug disposition with drug-drug interaction, Part II: competitive and uncompetitive cases.
    Koch G; Jusko WJ; Schropp J
    J Pharmacokinet Pharmacodyn; 2017 Feb; 44(1):27-42. PubMed ID: 28074396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A two-dimensional mathematical model of non-linear dual-sorption of percutaneous drug absorption.
    George K
    Biomed Eng Online; 2005 Jul; 4():40. PubMed ID: 15992411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Method to Assess Interactivity of Drugs with Nonparallel Concentration Effect Relationships.
    Zhao L; Au JL; Wientjes MG
    Curr Cancer Drug Targets; 2017; 17(8):735-755. PubMed ID: 28359247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of drug interactions relevant to pharmacodynamic indirect response models.
    Earp J; Krzyzanski W; Chakraborty A; Zamacona MK; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2004 Oct; 31(5):345-80. PubMed ID: 15669772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mathematical formulation of additivity for antimicrobial agents.
    Boucher AN; Tam VH
    Diagn Microbiol Infect Dis; 2006 Aug; 55(4):319-25. PubMed ID: 16626903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling and simulation in molecular pharmacology.
    Mihalas GI; Kygyosi A; Lungeanu D; Vernic C
    Stud Health Technol Inform; 1998; 52 Pt 1():372-5. PubMed ID: 10384481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantifying biological activity in chemical terms: a pharmacology primer to describe drug effect.
    Kenakin T
    ACS Chem Biol; 2009 Apr; 4(4):249-60. PubMed ID: 19193052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of covariance between random effects in design for nonlinear mixed-effect models with an illustration in pediatric pharmacokinetics.
    Dumont C; Chenel M; Mentré F
    J Biopharm Stat; 2014; 24(3):471-92. PubMed ID: 24697342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fitting models for the joint action of two drugs using SAS.
    Whitehead A; Whitehead J; Todd S; Zhou Y; Smith MK
    Pharm Stat; 2008; 7(4):272-84. PubMed ID: 17979217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs.
    Borghardt JM; Weber B; Staab A; Kloft C
    AAPS J; 2015 Jul; 17(4):853-70. PubMed ID: 25845315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic modeling in vivo.
    Holford NH; Sheiner LB
    Crit Rev Bioeng; 1981; 5(4):273-322. PubMed ID: 7023829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of Analysis Methods for Assessment of Pharmacodynamic Interactions Including Design Recommendations.
    Chen C; Wicha SG; Nordgren R; Simonsson USH
    AAPS J; 2018 Jun; 20(4):77. PubMed ID: 29931471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [General pharmacodynamic principles].
    Bernard JP; Opdal MS; Khiabani H
    Tidsskr Nor Laegeforen; 2006 Aug; 126(16):2107-9. PubMed ID: 16932780
    [No Abstract]   [Full Text] [Related]  

  • 17. In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect.
    Tubic M; Wagner D; Spahn-Langguth H; Bolger MB; Langguth P
    Pharm Res; 2006 Aug; 23(8):1712-20. PubMed ID: 16832615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.
    Holford NH; Sheiner LB
    Clin Pharmacokinet; 1981; 6(6):429-53. PubMed ID: 7032803
    [No Abstract]   [Full Text] [Related]  

  • 19. Quantifying synergism/antagonism using nonlinear mixed-effects modeling: a simulation study.
    Boik JC; Newman RA; Boik RJ
    Stat Med; 2008 Mar; 27(7):1040-61. PubMed ID: 17768754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using pharmacokinetic-pharmacodynamic relationships to predict the effect of poor compliance.
    Boissel JP; Nony P
    Clin Pharmacokinet; 2002; 41(1):1-6. PubMed ID: 11825093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.